x
Filter:
Filters applied
- Editorials
- Fricker, MichaelRemove Fricker, Michael filter
- Niessen, Natalie MRemove Niessen, Natalie M filter
- 2022 - 2023Remove 2022 - 2023 filter
Editorials
1 Results
- Review
T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma
Annals of Allergy, Asthma & ImmunologyVol. 129Issue 2p150–159Published online: April 26, 2022- Natalie M. Niessen
- Michael Fricker
- Vanessa M. McDonald
- Peter G. Gibson
Cited in Scopus: 3T2-low asthma is an often severe asthma subtype with limited treatment options and biologic therapeutics are lacking. Several monoclonal antibodies (mAbs) targeting non-T2 cytokines were previously reported to be ineffective in asthma. These trials often investigated heterogeneous asthma populations and negative outcomes could be related to unsuitable study cohorts. More tailored approaches in selecting participants based on specific biomarkers have been beneficial in treating severe T2-high asthma.